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ABSTRACT 
 Osteosarcoma (OS) is the most common primary bone malignancy in children and 
adolescents. More than 30% of patients develop lung metastasis, which is the leading cause of 
mortality. Recently, the extracellular matrix protein Cyr61 has been recognized as a malignancy 
promoting protein in OS mouse model with prognostic potential in human OS. In this study, we 
aimed at the identification of novel Cyr61-interacting proteins. 
 Here we report that Cyr61 associates with Caprin-1, and confocal microscopy showed that 
stable ectopic expression of Caprin-1 leads to the formation of stress granules containing Caprin-
1 and Cyr61, confers resistance to cisplatin-induced apoptosis, and resulted in constitutive 
phosphorylation of Akt and ERK1/2. Importantly, ectopic expression of Caprin-1 dramatically 
enhanced primary tumor growth, remarkably increased lung metastatic load in a SCID intratibial 
OS mouse model, and decreased significantly (p<0.0018) the survival of the mice. Although 
Caprin-1 expression, evaluated with a tissue microarray including samples from 59 OS patients, 
failed to be an independent predictor for the patients’ outcome in this limited cohort of patients, 
increased Caprin-1 expression indicated a tendency to shortened overall survival, and more 
strikingly, Cyr61/Caprin1 co-expression was associated with worse survival than that observed 
for patients with tumors expressing either Cyr61 or Caprin-1 alone or none of these proteins. The 
findings imply that Caprin-1 may have a metastasis promoting role in OS and show that through 
resistance to apoptosis and via the activation of Akt and ERK1/2 pathways, Caprin-1 is 
significantly involved in the development of OS metastasis. 
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model 
 
      Sabile et al. 
3 
1. Introduction 
 Osteosarcoma (OS) is the most common highly malignant primary bone tumor of children 
and young adults [1]. OS has a high propensity for lung metastasis which is the main cause of 
death of OS patients [2, 3]. The cellular and molecular events that initiate and propagate 
osteosarcomagenesis remain poorly understood [4, 5]. Thus, a more detailed understanding of the 
molecular pathophysiological mechanisms causing OS and metastasis is required for the 
development of more effective therapeutics and/or a more personalized therapy. Recently, our 
group and others found that the expression of Cyr61 in primary tumor tissue correlated with poor 
prognosis for the OS patients and that overexpression of Cyr61 in experimental OS in mice 
enhanced lung metastasis [6, 7]. Cyr61, a member of the CCN (CYR61/CTGF/NOV) family, is a 
multifunctional matricellular protein with regulatory functions in several processes involved in 
tumor biology, and for which aberrant expression was associated with a myriad of pathologies, 
including various cancers [8-12]. Cyr61 can either associate with the extracellular matrix and cell 
surfaces or localizes in the cytoplasm and nucleus [13].  
 In the present study, we aimed at the identification of novel Cyr61-interacting proteins. By 
combined Cyr61 immunoprecipitation and mass-spectrometric analysis, we identified Caprin-1 
(cytoplasmic activation/proliferation-associated protein1) as a novel Cyr61-interacting protein. 
Caprin-1 is a member of a family of cytoplasmic proteins that is highly conserved in vertebrates 
and that tightly correlates with cell proliferation [14], and is required for normal progression 
through the G1-S phase of the cell cycle [15, 16]. The amino acid sequence of Caprin-1, 
consisting of 709 amino acids, contains an RGG motif characteristic for RNA-binding proteins 
[14]. Indeed, Caprin-1 was found to accumulate in the leading edge of migrating cells and was 
shown to co-localize with the GTPase-activating protein Src homology 3 domain binding protein 
(G3BP-1) in cytoplasmic RNA granules associated with microtubules [17, 18]. Interestingly, 
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Caprin-1 associates with another form of RNA granule in cell lines, cytoplasmic stress granules 
(SG) which are cytoplasmic aggregates that regulate translation of subsets of mRNA following 
exposure to environmental stress. Caprin-1 has been shown to be a component of the SG in HeLa 
cells and ectopic expression of Caprin-1 protein alone is sufficient to induce SG formation and 
phosphorylation of the eukaryotic translation initiation factor 2α (eIF-2α) through Caprin-1’s 
ability to bind mRNAs [17]. On the other hand, the expression of Caprin-1 was shown to be 
suppressed by either overexpression of wild-type p53 (wt-p53) [19] or by interaction of miR-16 
with the 3′ UTR of Caprin-1 mRNA [20]. 
 In this study, we identified Caprin-1 as a Cyr61-interacting protein. We report that stable 
ectopic expression of Caprin-1 provoked co-accumulation with Cyr61 in SG, structures known to 
be involved in apoptosis protective processes. We further show that forced expression of Caprin-
1 confers to the cells a more resistant phenotype to cisplatin-induced apoptosis, and leads to a 
constitutive activation of the Akt and ERK1/2 signaling pathways. Importantly, ectopic 
expression of Caprin-1 enhanced primary tumor growth, remarkably increased lung metastatic 
load in an intratibial OS model in SCID mice, and decreased significantly the survival of the 
mice. Our findings suggest that Caprin-1 may function as a tumor promoter in OS metastasis and 
elucidate a novel role of Caprin-1 in OS pathogenesis and metastasis.  
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2. Materials and Methods 
2.1. Cell culture and transfection 
 Human SaOS-2 (HTB-85) and U2OS OS cells were cultured as previously described [7]. 
SaOS-2 and U2OS cells stably over-expressing Caprin-1 with an N-terminal Flag-tag (SaOS-
2/Caprin-1 and U2OS/Caprin-1) were obtained by calcium phosphate precipitation-mediated 
transfection [21] with the plasmid pCMV-Tag4-Flag-Caprin-1 and subsequent selection for 
neomycin resistance with 500 µg/ml G418 (Invitrogen, Carlsbad, CA, USA). Control SaOS-2 or 
U2OS cells transfected with the pCMV-Tag4 empty vector (SaSO-2/EV or U2OS/EV cells) were 
obtained accordingly.  
 
2.2. Purification of Cyr61-interacting proteins and mass spectrometry  
 For the identification of Cyr61-interacting proteins, lysates of SaOS-2 OS cells were 
prepared as described previously [7]. Supernatants were collected and incubated at 4°C overnight 
with Cyr61 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The 
immunocomplexes were adsorbed to protein A/G Plus-Agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The beads were washed 4 times with lysis buffer before 
the proteins were eluted with Laemmli buffer and separated by 6%-15% gradient sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were stained with Coomassie 
(Coomassie G250, BioRad Laboratories, Hercules, CA, USA), selected protein bands were 
excised and digested with trypsin. The generated peptides were analyzed by nanoLC-MS/MS on 
a LCQ Deca XP (Thermo Scientific) and identified with MASCOT (Matrix Science) searching 
the data base UniProtKB/Swiss-Prot 2011_08.  
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2.3. Generation of Caprin-1 antibodies  
 The peptide NH2-CSHATEQRPQKEPID-CONH2 corresponding to amino acid sequence 
452 to 465 of human Caprin-1, was chemically cross-linked to keyhole limpet hemocyanin 
(KLH). The conjugation product was used by Pineda Antikörper-Service (Berlin, Germany) for 
the immunization of three rabbits. Caprin-1 affinity-purified antibodies obtained from Pineda 
Antikörper-Service were screened by Western blot analysis of extracts of SaOS-2 and of SaOS-
2/Caprin-1 cells.  
 
2.4. Immunocytochemistry and confocal laser microscopy 
 Cells grown on glass coverslips were fixed with 3.7% formaldehyde in phosphate-buffered 
saline (PBS) for 15 min and permeabilized with 0.2% Triton X-100. The fixed cells were treated 
with blocking solution (2% fetal bovine serum in PBS) and stained with mouse anti-Cyr61 (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-Caprin-1, or goat anti-TIA1 (Santa Cruz) 
in blocking solution (1:400) at room temperature for 1 h. Cells were washed 3 times with PBS, 
and stained with FITC-labeled donkey anti-mouse, Dylight 594-labeled donkey anti-rabbit, or 
Cy5-labeled donkey anti-goat secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., 
Baltimore, Pike West Grove, USA) at room temperature for 1 h. Nuclear DNA was stained with 
0.2 µg/ml 4′,6′-diaminidino-2-phenylindole (DAPI, Molecular Probes Inc, Eugene, USA). 
Fluorescence imaging was performed with a confocal laser scanning microscope (SP5, Leica, 
Heerbrugg, Switzerland) equipped with a Plan-Apochromat 63 x NA 1.4 oil immersion objective. 
 
2.5. Immunoprecipitation and immunoblotting 
 Proteins were extracted from cultured cell lines and immunoblotted as described previously 
[7]. For immunoprecipitation, 500 µg of lysate in lysis buffer were pre-cleared by incubation with 
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50 µl of protein A/G Plus-Agarose beads (Santa Cruz) at 4°C for 1 h and centrifugation at 5000 g 
for 2 min. 10 µg of Caprin-1 or Cyr61 antibodies or of control immunoglobulin G (IgG) were 
then added to the supernatants and the samples agitated at 4°C overnight. Subsequently, 50 µl of 
protein A/G Plus-Agarose beads were added and the samples incubated at 4°C for 90 min. After 
centrifugation at 5000 g for 2 min, pelleted beads were washed 4 times with lysis buffer and 
bound proteins were eluted by boiling in Laemmli buffer and subjected to SDS-PAGE. Proteins 
in immunoprecipitation, signaling and apoptosis experiments were then analyzed with antibodies 
to human Caprin-1, Cyr61 and GAPDH (Santa Cruz), Flag (Sigma, Buchs, Switzerland), 
phospho-Akt, Akt, phospho-ERK1/2 and ERK1/2, caspase 3, and PARP (Cell Signaling 
Technology, Danvers, MA, USA). The apoptosis-provoking chemotherapeutic drug Cisplatin 
was purchased from Sigma. 
 
2.6. Intratibial human OS xenograft model in SCID mice 
 The mice were housed and the tumor cells inoculated as reported and in accordance with the 
guidelines of the ‘‘Schweizer Bundesamt für Veterinärwesen’’ and of the local authorities [7]. 
Briefly, 5 x 105 SaOS-2/EV or SaOS-2/Caprin-1 cells in 10 µl PBS were injected intramedullary 
into the left tibia of individual mice under X-ray control with a MX-20 DC Digital Radiography 
System (Faxitron X-Ray Corporation, Lincolnshire, IL, USA). The health status of the mice was 
monitored three times a week and primary tumor growth examined in 2-week intervals by X-ray 
and by calculating the tumor volume from measurements of the legs with a caliper. The equation 
length x (width)2/2 of the tumor bearing tibia minus length x (width)2/2 of the control tibia was 
used. 
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2.7. Histology of lung metastases 
 On the day of sacrifice, the lungs of the mice were prepared, fixed and embedded into 
paraffin as described [7]. Ten 5 µm sections were collected at 200 µm intervals from each lung 
and mounted on SuperFrost®Plus slides (Menzel GmbH & Co KG, Braunschweig, Germany) and 
then processed for hematoxylin-eosin (HE) staining according to standard protocols. The total 
area of all metastatic lesions recognized on an individual section was determined with a 
MATLAB (v2009b, Mathworks, MA) custom made program. Images were first converted into 
binary images. Total lung tissue area was determined with a morphological close operation to 
remove small gaps in between tissue and highlighted in red. Metastatic lesions (target area) were 
identified with a morphological open operation to remove areas of normal lung tissue and were 
highlighted in green. To assess the proliferation index in vivo, we used immunoreactive Ki67 in 
primary tumor and lung tissue sections as a marker of proliferation. Ki67 was immunostained 
with rabbit polyclonal Ki67 antibody (Abcam, Cambridge, UK), and the immunostaining was 
visualized with peroxidase-conjugated secondary antibodies (Vector Laboratories Inc., 
Burlingeme, CA, USA), Vectastain® Elite ABC and a substrate-chromogen system (Dako, Baar, 
Switzerland). 
 
2.8. Human OS tissue microarray, Caprin-1 immunostaining and Kaplan-Meier analysis  
 Primary osteosarcoma biopsies of 59 patients and normal bone tissue specimens were 
collected between June 1990 and December 2005 according to the regulations of the Swiss ethics 
committee. Clinical information on the patients included is summarized in Table 1. The tissue 
microarray (TMA) was arranged and 4.5 µm tissue sections were processed as previously 
described [7, 22], stained with Caprin-1 or Cyr61 antibodies (1:400) and counterstained with 
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haematoxylin. The grading of the TMA was performed based on both, the intensity and the 
percentage of stained area. The intensity of the staining was evaluated by eye by two independent 
investigators and the percentage of stained areas was calculated with a custom MATLAB 
program. Immunostained (brown) and non-stained (blue) areas were determined by color 
deconvolution [23]. The percentage of Caprin-1 or Cyr61 expressing tissue area was defined as 
brown area (number of brown pixels) divided by the total tissue area (number of blue and brown 
pixels) x 100. Kaplan-Meier analysis was used to correlate Caprin-1 or/and Cyr61 expression 
with overall survival of the patients.  
 
2.9. Statistical analysis 
 Results for the in vivo experiments are presented as mean ± standard error of the mean 
(SEM), and quantification results of the Western blots are presented as the mean ± standard 
deviation (SD). Differences between means were analyzed for significance by unpaired t-test 
with GraphPad Prism® 5.01 software. The Kaplan–Meier analysis was statistically analysed with 
the log-rank test. p≤0.05 was considered statistically significant. 
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3. Results 
3.1. Identification of Caprin-1 as a novel Cyr61-interacting protein 
 In search of novel Cyr61-interacting proteins, Cyr61 was immunoprecipitated from SaOS-2 
OS cell extracts with affinity purified Cyr61 polyclonal antibodies. Subsequent mass 
spectrometric analysis of co-precipitated proteins identified among others Caprin-1, a well 
conserved cytoplasmic protein that is involved in the regulation of cell proliferation (Fig. 1A). As 
described in the Materials and Methods section, we generated affinity-purified Caprin-1 
antibodies in rabbits. On Western blots of proteins extracted from SaOS-2 and SaOS-2/EV cells, 
Caprin-1 antibodies recognized a single prominent protein with the expected molecular weight of 
116 kDa (Fig. 1B, lanes 1 and 3). The specificity of Caprin-1 antibodies was further confirmed 
by Western blot analysis of protein extracts of SaOS-2/Caprin-1 cells overexpressing Flag-tagged 
Caprin-1. Caprin-1 antibodies recognized Flag-tagged Caprin-1, also recognized by Flag 
antibodies, and endogenous Caprin-1, which on 6% SDS-PAGE, migrated slightly faster than 
Flag-tagged Caprin-1 and was also present in extracts of control non-transfected SaOS-2 cells 
and in SaOS-2/EV cells (Fig. 1B). The Caprin-1 antibodies were also suitable for 
immunocytochemistry and localized endogenous Caprin-1 in the cytoplasm of SaOS-2 cells as 
expected (Fig. 1C) [14, 17]. 
 
3.2. Interaction and co-localization in stress granules of Caprin-1 and Cyr61  
 The interaction of Caprin-1 and Cyr61 was further confirmed by co-immunoprecipitation of 
the two proteins in both directions using SaOS-2 cell extracts. As shown before, 
immunoprecipitates obtained with Cyr61 antibodies contained Cyr61 and Caprin-1, but, 
importantly, Caprin-1 antibodies precipitated Caprin-1 together with Cyr61 (Fig. 2A). In control 
precipitates of SaOS-2 cell extracts with rabbit IgG, Caprin-1 and Cyr61 remained undetectable.  
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 Consistent with a stable interaction between Caprin-1 and Cyr61 in living cells, 
immunofluorescent staining of the two proteins in SaOS-2/Caprin-1 cells combined with 
confocal microscopy co-localized the two proteins in cytoplasmic granule-like structures (Fig. 
2B). Interestingly, earlier studies in HeLa cells overexpressing Caprin-1 showed accumulation of 
the protein in cytoplasmic stress granules (SG), characterized by immunostaining with specific 
antibodies to the well-established SG marker T-cell restricted antigen 1 (TIA1), which is 
normally localized in the nucleus [17, 24]. Therefore, we hypothesize that the cytoplasmic 
granule-like structures in Fig. 2B might be SG. Interestingly, only cells that highly expressed 
Caprin-1 showed stress granule formation and are co-stained with TIA1 (Fig. 2C, arrow), 
whereas cells expressing low levels of  Caprin-1 showed uniform nuclear TIA1-staining with no 
signs of stress granules (Fig. 2C, arrow head). These results indicate that overexpression of 
Caprin-1 in OS cells indeed provoked the formation of stress granules. Furthermore, triple 
immunostaining of Cyr61, Caprin-1 and TIA1 demonstrated Caprin-1 and Cyr61 co-localized 
within the SG (Fig. 2D). Taken together, this immunocytochemical analysis demonstrated that 
overexpression of Caprin-1 in SaOS-2 cells leads to the formation of SG and that the interaction 
of overexpressed Caprin-1 with endogenous Cyr61 results in co-accumulation of the two proteins 
in SG. 
 
3.3. Overexpression of Caprin-1 decreases the sensitivity of OS cells to cisplatin-evoked 
apoptosis  
 SG are subcellular structures that are involved in cell death protective processes. Cisplatin is 
one of the most commonly used chemotherapeutic drugs for the treatment of OS. However, 
resistance to cisplatin is a major cause of treatment failure in human OS [25]. Here, we 
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investigated the postulated anti-apoptotic activity of Caprin-1 by comparing the apoptotic 
potency of cisplatin in SaOS-2/EV and SaOS-2/Caprin-1 OS cells treated with increasing 
concentrations of the drug (0, 0.7, 3.5, 7 µg/ml) for 48 h. As readouts of cisplatin-evoked 
apoptosis, we examined on Western blots the cleavage of procaspase-3 and of PARP, a substrate 
of caspase-3, in extracts of non-treated and treated cells. Caspase-3 activation in SaOS-2/EV cells 
treated with the indicated concentrations of cisplatin resulted in a decrease in detectable levels of 
procaspase-3 (Fig. 3A). In SaOS-2/Caprin-1 cells, however, procaspase-3 levels were 
indistinguishable from those in non-treated control cells (Fig. 3A). The cleavage of PARP in 
SaOS-2/EV cells in response to cisplatin treatment was in perfect agreement with that observed 
for capsase-3 activation. In SaOS-2/Caprin-1 cells, on the other hand, cisplatin-evoked PARP 
cleavage was significantly less compared to that observed in SaOS-2/EV cells (Fig. 3B).  
Similarly, treatment of U2OS/EV cells with 3.5 µg/ml cisplatin resulted in a significant cleavage 
of both procaspase-3 and of PARP, whereas U2OS/Caprin-1, much like SaOS-2/Caprin-1 cells, 
are more resistant to cisplatin (Fig. 3C and 3D). Interestingly, pre-incubation of the cells with the 
pancaspase inhibitor Z-VAD prior to cisplatin treatment significantly inhibited the decrease in 
procaspase-3 and PARP cleavage (Fig. 3C and 3D) demonstrating that the observed cisplatin-
evoked apoptosis in OS cells is mainly caspase-dependent. Taken together, these results provide 
solid evidence for an apoptosis-protective activity of overexpressed Caprin-1 in two OS cell 
lines, SaOS-2 and U2OS.  
 
3.4. Caprin-1 overexpression activates Akt and ERK1/2 in OS cells 
 Caprin-1 is involved in the regulation of cell proliferation [14, 15]. The MAPK/ERK 
(mitogen-activated protein kinase/extracellular signal-regulated kinase) and PI3K/Akt (lipid 
kinase phosphoinositide-3-kinase) signaling pathways are well known to play an important role 
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in transduction of signals to the cell nucleus, where they influence the expression of genes that 
regulate important cellular processes such as cell proliferation, apoptosis and survival. We 
therefore investigated the status of the activation of Akt and ERK1/2 in two OS cell lines SaOS-2 
and U2OS. We found that overexpression of Caprin-1 in both OS cell lines increases 
significantly the levels of phosphorylated Akt and ERK1/2 (Fig. 4). These in vitro results thus 
indicate that, in SaOS-2 and U2OS cells, Caprin-1 activates the Akt and ERK1/2 signaling 
pathways and thereby suggest that Caprin-1 might have malignancy-enhancing properties in OS. 
 
3.5. Caprin-1 promotes intratibial primary tumor growth and lung metastasis in mice 
 In order to investigate a potential malignancy promoting role of Caprin-1 in OS, as suggested 
by its reported regulatory activities in cell proliferation [14, 15], and the constitutive activation of 
Akt and ERK1/2 shown above, we compared the growth and metastasis of primary intratibial OS 
tumors derived from SaOS-2/Caprin-1 and SaOS-2/EV cells in SCID mice. All mice injected 
with SaOS-2/Caprin-1 cells developed primary tumors that became visible on X-ray within 28 
days after tumor cell injection (Fig. 5A, bottom panels). In all mice injected with SaOS-2/EV 
control cells, on the other hand, primary tumors remained radiologically undetectable until day 64 
after tumor cell injection (Fig. 5A, top panels), but all these mice developed visible tumors 
between day 64 and day 90 post tumor cell inoculation. The tumors in all mice showed 
comparable osteolytic and osteoblastic lesions in the bone and the surrounding soft tissue (Fig. 
5A). A difference in volume between the tumor-bearing and the control leg in mice injected with 
SaOS-2/Caprin-1 cells was first observed 21 days after the injection. In control mice injected 
with SaOS-2/EV cells, measurable leg swelling was not observed before day 64 after tumor cell 
inoculation. These findings were consistent with the observed tumor progression monitored by 
X-ray. It is important to note that the mice injected with SaOS-2/Caprin-1 cells became moribund 
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and had to be sacrificed before the control mice even developed measurable or radiologically 
visible primary tumors (Fig. 5B). Accordingly, Kaplan-Meier survival curves plotted for the mice 
in the two groups indicated a significantly (p<0.0018) shorter mean survival of the SaOS-
2/Caprin-1 cell injected mice compared to SaOS-2/EV cell injected control animals (Fig. 5C). 
Interestingly, at sacrifice the mean size of primary tumors in the SaOS-2/Caprin-1 cell-injected 
mice was smaller to that in the control animals, suggesting that the mice with SaOS-2/Caprin-1 
cell-derived tumors suffered from severe metastasis. This was confirmed by histological 
examination of HE stained sections of the lungs. Although all SaOS-2/Caprin-1 cell injected mice 
were sacrificed at least 60 days before the first mouse in the control group had to be sacrificed, 
they showed more and larger metastatic foci in their lungs than the control mice (data not shown).  
 To confirm this observation, we performed a second study, an end-point study in which all 
mice of both SaOS-2/Caprin-1 and control groups, were sacrificed on the same day, at the time 
when the first animals in the SaOS-2/Caprin-1 group became moribund. In contrast to control 
mice with SaOS-2/EV cell-derived tumors, which showed metastatic lung lesions less than 1 mm 
in diameter (Fig. 6A, left panel), the mice with SaOS-2/Caprin-1 cell-derived tumors presented 
large lung metastases (Fig. 6A, right panel) and, as a consequence, the mean number of 
metastatic lesions per section was not representative for the metastatic load. Consequently, the 
metastatic load was defined as the percentage of metastatic tissue per lung tissue section 
estimated with a MATLAB program as described under Materials and Methods. In mice with 
SaOS-2/EV cell-derived tumors the mean area of metastatic tissue amounted to approximately 
5% of the total area (Fig. 6A, a-b), whereas lung sections of SaOS-2/Caprin-1 cell injected mice 
showed 44% metastatic tissue (Fig. 6A, c-d).  
 Furthermore, we assessed the proliferation index by Ki67 immunostaining of sections of 
primary tumors in mouse legs as well as sections of the lungs. Ki67 staining of the primary 
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tumors showed no significant difference in the percentage of proliferating cells in vivo (Fig. 6B, 
upper panels). Similarly, Ki67 staining of the lung metastatic nodules showed no significant 
difference in the percentage of proliferating cells (Fig. 6B, lower panels). Interestingly, beside the 
metastatic nodules, the healthy lung tissue of mice injected with SaOS-2/Caprin-1 cells appears 
to contain significantly more proliferative cells in comparison to the healthy lung tissue in control 
mice (Fig. 6B, lower panels). Altogether, the results of these in vivo experiments in mice 
confirmed the postulated more malignant phenotype of SaOS-2/Caprin-1 compared to SaOS-
2/EV cells that consequently accounted for the observed shorter survival of the SaOS-2/Caprin-1 
compared to the control SaOS-2/EV tumor bearing mice. 
 
3.6. Expression of Caprin-1 in human OS tissues 
 Based on our in vivo results, we hypothesized that the expression of Caprin-1 in human OS 
primary tumors might affect the aggressiveness of the disease and, consequently, the patient’s 
survival. The expression of Caprin-1 was therefore investigated immunohistochemically in OS 
primary tumor tissue on a tissue microarray (TMA). Representative immunohistochemical 
staining is shown in Fig. 7A. A Kaplan-Meier survival analysis demonstrated that, irrespective of 
metastatic or local disease, 43 patients with immunohistochemically detectable expression of 
Caprin-1 in tumor tissue had a shorter overall survival of 128 ± 12 months (mean ± SE) than 16 
patients with non-detectable Caprin-1 expression (mean overall survival of 173 ± 18 months). 
However, the difference in overall survival was not statistically significant (p=0.2056) (Fig. 7B). 
A second Kaplan-Meier survival analysis that, in addition to Caprin-1 expression, distinguished 
between patients with local or with metastatic disease revealed the shortest survival time of 53 ± 
12 months for 16 patients with metastases and positive expression of Caprin-1 (Fig. 7C). 
Interestingly, 6 patients with metastatic disease, but non-detectable Caprin-1 expression, survived 
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considerably longer (mean survival time of 116 ± 32 months), but the overall survival was again 
not significantly different from that of the patients with Caprin-1 expressing tumors (p=0.124). 
Thus, despite the relatively small number of patients examined, our findings implicate that 
Caprin-1 might be associated with worse outcome of OS patients. Strikingly, a Kaplan-Meier 
survival analysis combining robust expression of both Caprin-1 and Cyr61 demonstrated that the 
overall survival of the patients with Caprin-1 and Cyr61 co-expressing tumours was significantly 
(p <0.05) shorter than that of patients who expressed in their tumours one or the other or none of 
the two proteins (Fig. 7D). Taken together, abundant expression of Caprin-1 in primary tumors of 
OS patients might at least in part contribute to its malignancy. 
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4. Discussion 
  Recent studies identified Cyr61 as a novel malignancy-enhancing molecule in 
experimental OS in mice and as an immunohistochemical marker in human OS tissue with 
prognostic potential for poor prognosis [6, 7]. In the present study, we undertook a proteomic 
approach, e.g. immunoprecipitation of Cyr61 combined with mass spectrometry, to identify 
proteins that, through interaction with Cyr61, may co-operate with the malignancy-promoting 
protein during tumor development and metastasis in OS. We identified Caprin-1 as a novel 
Cyr61-interacting protein and demonstrated that Caprin-1, similar to Cyr61 [7], has malignancy 
promoting properties in experimental intratibial OS in SCID mice when overexpressed in the 
inherently low metastatic human SaOS-2 OS cell line.  
 First, we confirmed the Cyr61/Caprin-1 interaction in intact cells and investigated cellular 
responses to Caprin-1 overexpression in vitro. In an effort to find subcellular structures and 
locations where Cyr61 and Caprin-1 interact, confocal imaging revealed predominant co-
localization of Cyr61 and Caprin-1 in SG, identified by TIA1 staining, a specific marker for these 
cellular structures. Interestingly, SG formation in response to overexpression of Caprin-1 has 
been reported [17, 26] and selective binding of Caprin-1 to mRNA encoding c-Myc and cyclin 
D2 in SG was observed [17]. SG are multi-molecular aggregates of stalled translation pre-
initiation complexes that prevent the accumulation of misfolded proteins [27]. SG and their 
components have been implicated in the pathogenesis of several diseases including cancer [24, 
28]. SG arise in response to cell stress and are considered as subcellular structures that are 
involved in cell death protective processes. This was proposed based on the observation that 
stress-exposed cells with impaired SG assembly showed poor survival [29-31]. In cells with 
irreversible damage caused by stress, however, SG appeared to direct these cells to apoptosis [24, 
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32]. Along these lines, SG were shown to also contain apoptosis regulatory factors in addition to 
RNA-protein complexes [24, 32].   
 These previously reported findings together with our new results describing a diminished 
cisplatin-provoked apoptotic response of cells overexpressing Caprin-1 compared to control cells, 
point to a hitherto unknown apoptosis-protective function of Caprin-1. It is conceivable that the 
co-accumulation of Caprin-1 and Cyr61 in SG reflects one apoptosis-protective activity of 
Caprin-1. Among other cellular roles, Cyr61 is known to have apoptosis and senescence 
promoting functions through interaction with integrin α6β1 and heparan sulfate proteoglycans 
[33]. Thus, it is tempting to speculate that Caprin-1, reported to be a component of SG, may 
sequester some proteins, including Cyr61, to SG and thereby transiently neutralize their activity. 
A similar mechanism of protein-inactivation by subcellular granular deposition has been reported 
for TNF-α receptor associated factor 2 (TRAF2). TRAF2 is sequestered by eIF4GI into heat 
shock-induced SG. This impairs TNF-α-mediated activation of NF-κB, which is a key 
transcriptional regulator of inflammatory responses and apoptosis [34].  
 Gene-targeting experiments, using homologous recombination to disrupt caprin-1 alleles, 
showed that Caprin-1 is needed for normal progression through the G1-S phase of the cell cycle 
[15], but the corresponding molecular mechanisms employed by Caprin-1 are largely unknown. 
Down-regulation of Caprin-1 by miR-16 has been considered as a mechanism that may 
contribute to prolongation of the G1 phase of the cell cycle [20]. The present study, on the other 
hand, provides evidence for a regulatory function of Caprin-1 in Akt and ERK1/2 
phosphorylation, known to mediate signals that regulate multiple cellular processes including cell 
proliferation. Interestingly, overexpression of Caprin-1 in two OS cell lines led to elevated levels 
of phosphorylated Akt and ERK1/2 consistent with a constitutive activation of both signaling. 
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Surprisingly, however, proliferation rates of Caprin-1-overexpressing and of control SaOS-2/EV 
cells in vitro were not significantly different (not shown). 
 Despite these observations in vitro, constitutively elevated levels of phospho-Akt and -
ERK1/2 in Caprin-1 overexpressing OS cells might enhance their aggressiveness in vivo. This 
hypothesis was confirmed by the results of our study in the intratibial xenograft OS model in 
SCID mice, in which SaOS-2/Caprin-1 cells showed a strikingly enhanced malignant phenotype 
compared to control SaOS-2/EV cells. This was reflected by a remarkably faster growth of the 
primary intratibial tumors and of the metastatic lesions in the lungs and, consequently, by a 
significantly shorter survival of the mice injected with SaOS-2/Caprin-1 cells compared to the 
animals that received control SaOS-2/EV cells. Although the indistinguishable proliferation rates 
of the SaOS-2/Caprin-1 and of the SaOS-2/EV cells in vitro remain unexplained, the results of 
the animal studies are consistent with a growth promoting effect of Caprin-1 overexpression in 
SaOS-2 cells in both the bone and lung tissue environment, likely mediated by activation of Akt 
and ERK1/2 pathways. The comparative histological analysis of the lungs of mice injected with 
SaOS-2/Caprin-1 cells and of animals injected with SaOS-2/EV cells suggested that the observed 
massive increase in lung metastatic load upon Caprin-1 overexpression was mainly caused by a 
faster and more invasive growth of the cells in lung tissue rather than by an increase in the 
number of cells metastasizing from the primary tumors. These observations are different from our 
findings in mice with Cyr61 overexpressing SaOS-2 cell-derived intratibial tumors and lung 
metastases [7].  These mice showed not only larger lung lesions, but also a significantly higher 
density of lung metastases than mice bearing SaOS-2/EV cell-derived primary tumors. Thus, 
SaOS-2/Caprin-1 and SaOS-2/Cyr61 cells exhibit a slightly different phenotype when developing 
to metastatic lesions in the lungs of SCID mice, but both proteins enhanced the aggressiveness of 
SaOS-2 cells. Strikingly, a Kaplan-Meier survival analysis correlating Caprin-1 and Cyr61 
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immunostaining of OS tissues with the survival of the patients, showed that Caprin1/Cyr61 co-
expression was associated with significantly worse survival of these patients compared to the 
patients with tumors that expressed only one or none of the two proteins. These results are in 
good agreement with our findings in the experimental OS model in SCID mice and suggest 
indeed an in vivo cooperation between Caprin-1 and Cyr61 that enhances OS malignancy. 
Collectively, the proposed apoptosis-protective activities of Caprin-1 overexpression together 
with the constitutive activation of Akt and ERK1/2 signaling are consistent with the observed 
malignancy-promoting properties of Caprin-1 protein in SaOS-2 OS cells in vivo.  
 
5. Conclusion 
 This study identifies Caprin-1 as a novel Cyr61-interacting protein and elucidates a novel 
function of Caprin-1. Forced expression of Caprin-1 in the human SaOS-2 and U2OS OS cell 
lines provoked co-accumulation with Cyr61 in stress granules, known to be involved in apoptosis 
protective processes. Importantly, we found that SaOS-2 and U2OS cells overexpressing Caprin-
1 are more resistant to cisplatin-induced apoptosis. Furthermore, Caprin-1 overexpression 
constitutively activated Akt and ERK1/2 signaling in both OS cell lines. These observations at 
the cellular level are consistent with the strikingly enhanced malignant phenotype of SaOS-2 OS 
cells overexpressing Caprin-1 compared to control cells in an orthotopic OS mouse model. 
Finally, our immunostaining analysis of Caprin1/Cyr61 co-expression in human OS tissues 
suggests an in vivo cooperation between Caprin-1 and Cyr61. From this and previous studies, 
which focused on Cyr61 [6, 7], we conclude that both Caprin-1 and Cyr61, at elevated expression 
levels in human OS, have related and additive, but distinct OS malignancy-enhancing properties 
in addition to largely unknown interaction-dependent functions that are currently under 
investigation.
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Legends to figures 
Fig. 1. Identification of Caprin-1 as a novel Cyr61-interacting protein. (A) SDS-PAGE of 
proteins immunoprecipitated from SaOS-2 cell extracts with control rabbit IgG (lane 1) or rabbit 
antibodies to Cyr61 (lane 2). MW: molecular weight markers. Cyr61 (predicted size: 39 kDa) and 
co-precipitated Caprin-1 (predicted size: 116 kDa), identified by mass spectrometry, were 
recognized in lane 2 and non-detectable control IgG (lane 1). (B) Validation of custom-made 
Caprin-1 affinity-purified rabbit antibodies (Caprin-1 antibodies). 6% SDS-PAGE and Western 
blot analysis of whole-cell extracts of SaOS-2 (lane 1), of SaOS-2/Caprin-1 and of control SaSO-
2/EV OS cells (lane 3) with Caprin-1 antibodies (top panel) or with antibodies to Flag (middle 
panel) or to the protein loading control GAPDH (bottom panel), revealed indicated protein 
components of the predicted size. (C) Cytoplasmic localization of Caprin-1 with Caprin-1 
antibodies in SaOS-2 cells with DAPI-stained nuclei in blue (scale bar, 50 µm).  
 
Fig. 2. Caprin-1 and Cyr61 co-immunoprecipitation and co-localization in stress granules of 
SaOS-2/Caprin-1 cells. (A) Co-immunoprecipitation of Cyr61 and Caprin-1 with antibodies to 
Cyr61 or to Caprin-1 from extracts of SaOS-2 cells visualized on Western blots with antibodies 
to Caprin-1 (top panel) or to Cyr61 (bottom panel). Total cell extract (lane 1), control 
immunoprecipitation (IP) with rabbit IgG (lane 2), or with Cyr61 (lane 3) or with Caprin-1 
antibodies (lane 4). (B) Immunofluorescent staining of Cyr61 (green), of Caprin-1 (red) and 
nuclear staining with DAPI (blue) in SaOS-2/Caprin-1 cells co-localized Caprin-1 and Cyr61 
(yellow) in cytoplasmic granule-like structures, as shown by confocal microscopy in overview 
images (top panels; scale bar, 20 µm) and in high magnification images of the boxed area 
(bottom panel; scale bar, 5 µm). (C) SaOS-2/Caprin-1 cells with low levels of exogenous Caprin-
1 (arrow heads), unlike cells with high levels of exogenous Caprin-1 (arrow), lacked stress 
granules as shown by uniform cytoplasmic TIA1 immunostaining (red) visualized by confocal 
microscopy (scale bar, 10µm). (D) Immunofluorescent staining of Cyr61 (green) and Caprin-1 
(red) in stress granules identified by TIA1 (grey) and visualized by confocal microscopy in 
overview images (top panels; scale bar, 40 µm) and at high resolution of the boxed area (bottom 
panels; scale bar 5 µm). Co-localization in the merged images on the far right in white. 
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Fig. 3. Overexpression of Caprin-1 in OS cells inhibits apoptosis. (A) Representative Western 
blot analysis of procaspase-3 and PARP cleavage in SaOS-2/EV cells (lanes 1) and in SaOS-
2/Caprin-1 cells (lanes 2) in response to treatment for 48 h with indicated doses of cisplatin. Total 
cell extracts were analyzed with antibodies to procaspase 3, to PARP and to GAPDH used as a 
protein loading control.  (B) Quantitative analysis of PARP cleavage of three independent 
Western blot experiments. The data are shown as the mean ± SD of cleaved PARP normalized to 
the uncleaved PARP. (C) SaOS-2/EV (lanes 1) or SaOS-2/Caprin-1 (lanes 2) cells or (D) 
U2OS/EV (lanes 1) or U2OS/Caprin-1 (lanes 2) cells were either treated with the vehicle DMSO 
alone as a control, or with 3.5 µM cisplatin, or pre-treated for 2 h with 100 µM of the general 
caspase inhibitor Z-VAD-FMK prior to cisplatin treatment. Cell lysates were then subjected to 
immunoblot analysis for procaspase-3, PARP and GAPDH (upper panels). A quantitative 
analysis of PARP cleavage is shown in the lower panels. The results are shown as the mean ± SD 
of cleaved PARP normalized to the uncleaved PARP from four independent Western blot 
experiments, *P<0.05, **P<0.01, ***P<0.001. 
 
 
Fig. 4. Overexpression of Caprin-1 in OS cells activates Akt and ERK1/2. Representative 
Western blot of extracts of SaOS-2/EV (lane 1), SaOS-2/Caprin-1 (lane 2), U2OS/EV (lane 3) 
and U2OS/Caprin-1 (lane 4) OS cells, analyzed with antibodies to phospho-Ser473-Akt (p-Akt) 
and Akt (A), or with antibodies to phospho-ERK1/2 (p-ERK1/2), ERK1/2, and GAPDH (B) 
indicating constitutive phosphorylation of Akt and ERK1/2 in Caprin-1 overexpressing cells. 
Respective quantitative analysis of Western blots is indicated in the right panels. Bars are mean ± 
SD of p-Akt and p-ERK1/2 normalized to total Akt and total ERK1/2 respectively in individual 
protein extracts from three independent experiments, *P<0.05, **P<0.01. 
 
Fig. 5. Overexpression of Caprin-1 in SaOS-2 OS cells promotes intratibial primary tumor 
growth and consequently shortens animal survival. (A) Representative X-ray images of tumor-
bearing hind limbs of mice injected with SaOS-2/EV cells (EV, top panels) or with SaOS-
2/Caprin-1 cells (Caprin-1, bottom panels). The images show primary tumor appearance on 
indicated days after tumor cell injection. † = all mice injected with SaOS-2/Caprin-1 cells had to 
be sacrificed before the indicated days. (B) Intratibial primary tumor growth over time in mice 
injected with SaOS2/EV cells (blue) or with SaOS-2/Caprin-1 cells (red). (C) Kaplan-Meier 
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survival analysis indicating significantly (p<0.0018) shorter overall survival of mice injected with 
SaOS-2/Caprin-1 cells (red) compared to animals with SaOS2/EV cell-derived tumors (blue).  
*: Due to restrictions for animal experiments imposed by the local ethical authorities, we injected 
SaOS-2/Caprin-1 and SaOS-2/EV cells in SCID mice at the same time as we injected SaOS-
2/Cyr61 cells [7], allowing us to use the SaOS-2/EV  injected mice as a control for both Cyr61 
and Caprin-1 experiments.   
 
Fig. 6. Overexpression of Caprin-1 in SaOS-2 OS cells promotes lung metastasis in SCID mice. 
(A) Representative images of HE stained lung sections of mice injected with SaOS2/EV cells 
(left panel) or with SaOS-2/Caprin-1 cells (right panel). Metastatic lesions appearing as dense HE 
stained areas were labeled in green (a, c) and healthy lung tissue in red (b, d) for quantitative 
analysis of respective areas with the MATLAB program. (B) Representative images of Ki67 
immunostained sections of primary tumor tissue in hind limbs (upper panels) and Ki67-stained 
sections of lungs (lower panels) of mice injected with SaOS-2/EV cells (left panels) or with 
SaOS-2/Caprin-1 cells (right panels). 
 
Fig. 7. Kaplan-Meier analysis correlating immunohistochemical staining of Caprin-1 in human 
OS tissues in a tissue microarray with overall survival of the patients. (A) Representative images 
of tumor tissue microarray sections showing entire spots (upper panels) and higher magnification 
(lower panel) with non-detectable (left), moderate (middle) and intense (right) Caprin-1 
immunostaining. (B) Overall survival of OS patients with non-detectable (Caprin-1 neg) or 
detectable (Caprin-1 pos) immunostaining of tumor tissue. (C) Overall survival of patients 
without (Mets neg) or with (Mets pos) metastases and Caprin-1 neg or Caprin-1 pos tumors. (D) 
Overall survival of patients with tumors expressing both Caprin-1 and Cyr61 (Caprin-1 & Cyr 61 
pos) compared to the survival of all other patients.  
 
 
